Search Results - "Buttigliero, C."

Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs by Turco, Fabio, Gillessen, Silke, Cathomas, Richard, Buttigliero, Consuelo, Vogl, Ursula Maria

“…Metastatic castration resistant prostate cancer (CRPC) is an inevitably fatal disease. However, in recent years, several treatments have been shown to improve…”
Get full text

First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin by Iacovelli, R., Ciccarese, C., Brunelli, M., Battelli, N., Buttigliero, C., Caserta, C., Buti, S., Santini, D., Carella, C., Galli, L., Verri, E., Ermacora, P., Merler, S., Masini, C., De Vivo, R., Milesi, L., Spina, F., Rizzo, M., Sperduti, I., Fornarini, G., Tortora, G.

“…Cisplatin-based chemotherapy is the most recommended treatment for metastatic urothelial cancer (mUC). However, about 50% of patients are considered to be…”
Get full text

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2 by Caffo, O., Zagonel, V., Baldessari, C., Berruti, A., Bortolus, R., Buti, S., Ceresoli, G.L., Donini, M., Ermacora, P., Fornarini, G., Fratino, L., Masini, C., Massari, F., Mosca, A., Mucciarini, C., Procopio, G., Tucci, M., Verri, E., Zucali, P., Buttigliero, C.

Get full text

Pathological and molecular features of adrenocortical carcinoma: an update by Volante, M, Buttigliero, C, Greco, E, Berruti, A, Papotti, M

“…The pathological diagnosis of adrenocortical carcinoma (ACC), which is based on gross and microscopic criteria, is subjective. None of the features are…”
Get more information

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort by Fornarini, G., Rebuzzi, S.E., Banna, G.L., Calabrò, F., Scandurra, G., De Giorgi, U., Masini, C., Baldessari, C., Naglieri, E., Caserta, C., Manacorda, S., Maruzzo, M., Milella, M., Buttigliero, C., Tambaro, R., Ermacora, P., Morelli, F., Nolè, F., Astolfi, C., Sternberg, C.N.

“…Reliable and affordable prognostic and predictive biomarkers for urothelial carcinoma treated with immunotherapy may allow patients' outcome stratification and…”
Get full text

Immune-checkpoint inhibitors in previously treated patients with urothelial carcinoma: A systematic review and meta-analysis by De Luca, E., Di Nunno, V., Buttigliero, C., Tucci, M., Vignani, F., Zichi, C., Ardizzoni, A., Massari, F., Di Maio, M.

Get full text

674P Evaluation of cognitive function (CogF) in trials testing new-generation hormonal treatments (NGHT) in patients with prostate cancer (PC): A systematic review by Marandino, L., Buttigliero, C., Vignani, F., Gamba, T., Necchi, A., Tucci, M., Di Maio, M.

Get full text

1884MO Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study by Iacovelli, R., Ciccarese, C., Bersanelli, M., Zucali, P.A., Fantinel, E., Bimbatti, D., Verzoni, E., Accettura, C., Bonomi, L., Buttigliero, C., G. fornarini, Pipitone, S., Atzori, F., Masini, C., Massari, F., Primi, F., Buti, S., Perrino, M.R.A., Pafumi, S., Tortora, G.

Get full text

1355P Clinical trial enrollment among lung cancer patients: A real-world multicenter analysis by Reale, M.L., Capelletto, E., Buttigliero, C., Bordi, P., Ricciardi, S., Belluomini, L., Garbo, E., Leonetti, A., Lombardi, A., Dodi, A., Napoli, V., Casali, M., Soregaroli, D., Insolda, J., Bironzo, P., Tiseo, M., Migliorino, M.R., Pilotto, S., Passiglia, F., Novello, S.

Get full text

868P - Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): A network meta-analysis of randomized controlled trials (RCT) by Altavilla, A., Maio, M Di, Tucci, M., Lolli, C., Schepisi, G., Buttigliero, C., Vignani, F., De Giorgi, U.

“…Three recent RCT (Spartan, Prosper and Aramis) have demonstrated improved metastasis-free survival with new ARi Apalutamide (A), Enzalutamide (E) and…”
Get full text

Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): A network meta-analysis of randomized controlled trials (RCT) by Altavilla, A., Maio, M Di, Tucci, M., Lolli, C., Schepisi, G., Buttigliero, C., Vignani, F., De Giorgi, U.

Get full text

868PSafety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): A network meta-analysis of randomized controlled trials (RCT) by Altavilla, A, Maio, M Di, Tucci, M, Lolli, C, Schepisi, G, Buttigliero, C, Vignani, F, Giorgi, U De

“…Abstract Background Three recent RCT (Spartan, Prosper and Aramis) have demonstrated improved metastasis-free survival with new ARi Apalutamide (A),…”
Get full text

LBA26 Darolutamide maintenance in metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents (NHA) and non-progressive disease after subsequent treatment with a taxane: A randomized double-blind placebo-controlled phase II trial (SAKK 08/16) by Cathomas, R., Procopio, G., Hayoz, S., Kremer, E.A., Kienle, D., Caffo, O., Lorente, D., Pedrazzini, A., Roubaud, G., Nenan, S., Omlin, A.G., Buttigliero, C., Pereira Mestre, R.J., Ribi, K., Gillessen, S.

Get full text

619P Maintenance versus discontinuation of androgen deprivation therapy during docetaxel administration with a continuous or an intermittent schedule in metastatic, castration resistant, prostate cancer patients: A multicenter randomized phase III study of the Piemonte Oncology Network by Berruti, A., Mosca, A., Bianchi, S., Prati, V., Ortega, C., Buttigliero, C., Fea, E., Vanella, P., Valcamonico, F., Ciccone, G., Sirotova, Z., Chiappino, I., Canton, O. Dal, Masini, C., Sacco†, C., Amoroso, D., Montagnani, F., Comandone, A., Gennari, A., Tucci, M.

Get full text

768P Prognostic score combining systemic inflammation index (SII) and PD-L1 +/- LDH in advanced urinary tract carcinoma patients treated with atezolizumab: Subanalysis in the Italian population of the SAUL study by Rebuzzi, S.E., Sternberg, C.N., Fornarini, G., Calabro', F., Baldessari, C., Scandurra, G., De Giorgi, U., Masini, C., Naglieri, E., Caserta, C., Galli, L., Maruzzo, M., Zampiva, I., Buttigliero, C., Astolfi, C., Banna, G.L.

Get full text

First line avelumab in PD-L1+ve metastatic or locally advanced Urothelial Cancer (aUC) patients unfit for cisplatin: The ARIES trial by Iacovelli, R., Ciccarese, C., Brunelli, M., Battelli, N., Buttigliero, C., Caserta, C., Buti, S., Santini, D., Naglieri, E., Galli, L., Verri, E., Ermacora, P., Milella, M., Masini, C., Aprile, G., Milesi, L., Spina, F., Rizzo, M., Sperduti, I., Fornarini, G., Tortora, G.

Get full text

906PImmune-checkpoint inhibitors in previously treated patients with urothelial carcinoma: A systematic review and meta-analysis by De Luca, E, Di Nunno, V, Buttigliero, C, Tucci, M, Vignani, F, Zichi, C, Ardizzoni, A, Massari, F, Di Maio, M

Get full text

First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES study by Masini, C., Ciammella, P., Timon, G., Gnoni, R., De Giorgi, U.F.F., Bellia, S.R., Buti, S., Salaroli, F., Milella, M., Mazzarotto, R., Mucciarini, C., Vitale, M.G., Bruni, A., Procopio, G., Kinspergher, S., Nole, F., Morelli, F., Pappagallo, G., buttigliero, C., Pinto, C.

Get full text

961P - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES study by Masini, C., Ciammella, P., Timon, G., Gnoni, R., De Giorgi, U.F.F., Bellia, S.R., Buti, S., Salaroli, F., Milella, M., Mazzarotto, R., Mucciarini, C., Vitale, M.G., Bruni, A., Procopio, G., Kinspergher, S., Nole, F., Morelli, F., Pappagallo, G., buttigliero, C., Pinto, C.

“…NIVO is an anti-programmed cell death-1 (PD-1) monoclonal antibody; it might work even better when combined with SBRT improving clinical outcomes with a…”
Get full text

138P TALAPRO-1: Talazoparib (TALA) monotherapy in men with DNA damage response alterations (DDRalt) and metastatic castration-resistant prostate cancer (mCRPC): Exploration of DDRalt germline/somatic origin by Mehra, N., Fizazi, K., Laird, A.D., Barthélémy, P., Delva, R., Dorff, T., Maruzzo, M., Stirling, A., Machiels, J-P., Dumez, H., Renard, V., Albacker, L.A., Hopkins, J., Chen, H-C., Mata, M., Di Santo, N., Healy, C.G., van Oort, I.M., Buttigliero, C., de Bono, J.S.

Get full text